OSSINING, N.Y.--(BUSINESS WIRE)--HistoGenetics, a pioneer and global leader in high-resolution HLA typing services, today announced that it has received the prestigious Innovation Award from Be The Match®. Operated by the National Marrow Donor Program® (NMDP), Be The Match is an organization that matches donors to patients with life-threatening blood cancers, such as leukemia and lymphoma. It also educates healthcare professionals and conducts research so more lives can be saved. The award was presented last night at Be The Match’s annual Council Meeting in Minneapolis.
Dr. Nezih Cereb, co-founder and Chief Executive Officer of HistoGenetics, commented, “We are honored to be recognized for our contributions to this field. Be The Match operates the world's largest and most diverse donor registry in the world, with 16 million adult donors and 238,000 umbilical cord blood units, and we are proud that our advanced technology has been acknowledged by this important organization for its role in helping to save lives.”
Every three minutes someone is diagnosed with blood cancer in the US, and 70 percent of patients do not have a fully matched donor in their family. HLA typing, which is the analysis of genes in the human leukocyte antigen region of the human genome, is of critical importance for transplantation donor compatibility matching.
C. Randal Mills, Ph.D., Chief Executive Officer of Be The Match, and Jeffrey Chell, M.D., Chief Executive Officer Emeritus, said that the longstanding partnership with HistoGenetics and the company’s innovation in HLA testing lead to better matches and more cures.
“The collaboration between HistoGenetics and Be The Match exemplifies what we can achieve with shared vision and determination,” Chell said.
“We look forward to continuing to build upon this relationship as we search for more meaningful data in matching patients to their life-saving donation,” Mills added.
Dr. Soo Young Yang, Chairman and Founder of HistoGenetics, added: “Be The Match connects patients with their donor match for a marrow or umbilical cord blood transplant. We share the common goal of establishing such connections, as our mission is to provide tissue-typing services with the highest level of accuracy and quality assurance in a rapid turnaround time to help these life-saving matches become reality.”
HistoGenetics provides cost-effective HLA sequence-based typing services based on the latest state-of-the-art robotics and bioinformatics technologies for donor registries, pharmacogenomics, donor centers, cord blood typing, transplant centers, and HLA laboratories around the world. Through a proprietary process developed by Dr. Soo Young Yang and Dr. Nezih Cereb, HistoGenetics provides high- and low- throughput molecular tissue typing services at their high-tech facilities in the New York metropolitan area with an emphasis on extremely high quality and fast turnaround times. For more information, visit: www.histogenetics.com.
About Be The Match and NMDP
For people with life-threatening blood cancers—like leukemia and lymphoma—or other diseases, a cure exists. Be The Match® connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. People can contribute to the cure as a member of the Be The Match Registry, financial contributor or volunteer. Be The Match provides patients and their families one-on-one support, education, and guidance before, during and after transplant.
Be The Match is operated by the National Marrow Donor Program® (NMDP), a nonprofit organization that matches patients with donors, educates healthcare professionals and conducts research so more lives can be saved. To learn more about the cure, visit BeTheMatch.org or call 1 (800) MARROW-2.